ICON Public Limited Company (ICLR)
| Market Cap | 9.51B -19.3% |
| Revenue (ttm) | 8.10B -2.5% |
| Net Income | 599.48M -19.8% |
| EPS | 7.47 -16.8% |
| Shares Out | 76.36M |
| PE Ratio | 16.66 |
| Forward PE | 10.71 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 681,137 |
| Open | 124.97 |
| Previous Close | 125.00 |
| Day's Range | 120.34 - 128.95 |
| 52-Week Range | 66.57 - 211.00 |
| Beta | 1.23 |
| Analysts | Buy |
| Price Target | 182.91 (+46.93%) |
| Earnings Date | May 22, 2026 |
About ICLR
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient... [Read more]
Financial Performance
In 2024, ICLR's revenue was $8.28 billion, an increase of 1.99% compared to the previous year's $8.12 billion. Earnings were $791.47 million, an increase of 29.26%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for ICLR stock is "Buy." The 12-month stock price target is $182.91, which is an increase of 46.93% from the latest price.
News
HealthVerity to Acquire Symphony Health, Uniting Clinical Data and Commercial Analytics to Accelerate Breakthroughs Across the Healthcare Ecosystem
Philadelphia, PA, May 05, 2026 (GLOBE NEWSWIRE) -- HealthVerity, Inc., the leader in privacy-protected real-world data exchange and patient identity solutions, today announced that it has entered into...
Icon price target raised to $125 from $105 at Leerink
Leerink analyst Michael Cherny raised the firm’s price target on Icon (ICLR) to $125 from $105 and keeps an Outperform rating on the shares.
Icon says Audit Committee completes investigation into accounting practices
ICON (ICLR) announced that the Audit Committee of the Board of Directors has completed its investigation into certain of the Company’s accounting practices and controls. The Company reaffirmed that th...
ICON Provides Update on Audit Committee Investigation and Timing of Fourth Quarter and Full Year 2025 Financial Results
DUBLIN--(BUSINESS WIRE)--ICON Provides Update on Audit Committee Investigation and Timing of Fourth Quarter and Full Year 2025 Financial Results.
ICON plc options imply 12.4% move in share price post-earnings
Pre-earnings options volume in ICON (ICLR) plc is 2.0x normal with calls leading puts 5:1. Implied volatility suggests the market is anticipating a move near 12.4%, or $12.60, after results
ICON plc options imply 11.5% move in share price post-earnings
Pre-earnings options volume in ICON (ICLR) plc is 1.1x normal with puts leading calls 8:5. Implied volatility suggests the market is anticipating a move near 11.5%, or $13.52, after results
ICON plc options imply 9.7% move in share price post-earnings
Pre-earnings options volume in ICON (ICLR) plc is normal with calls leading puts 7:5. Implied volatility suggests the market is anticipating a move near 9.7%, or $11.49, after results are
Icon upgraded to Outperform from Market Perform at BMO Capital
BMO Capital analyst Sean Dodge upgraded Icon (ICLR) to Outperform from Market Perform with a price target of $130, up from $100. The firm’s recent analysis indicates continued improvements in
Icon, Advarra enter partnership, introduces ‘research-ready’ site network model
ICON (ICLR) and Advarra have entered a definitive partnership agreement to introduce a new ‘research-ready,’ connected site network model for clinical trials. The partnership will integrate ICON’s glo...
ICON and Advarra Introduce New ‘Research-Ready,' Connected Site Network Model
DUBLIN & COLUMBIA, Md.--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, and Advarra, the market leader in regulatory reviews and a leading provider of connect...
Lowey Dannenberg, P.C. is Investigating ICON PLC (NASDAQ: ICLR) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating ICON PLC (“ICON” or the “Company”) (NASDAQ:...
ICON plc options imply 2.8% move in share price post-earnings
Pre-earnings options volume in ICON (ICLR) plc is normal with calls leading puts 13:1. Implied volatility suggests the market is anticipating a move near 2.8%, or $2.71, after results are
Icon price target lowered to $120 from $200 at Citi
Citi analyst Patrick Donnelly lowered the firm’s price target on Icon (ICLR) to $120 from $200 and keeps a Neutral rating on the shares. The firm updated models in the
ICON plc options imply 4.1% move in share price post-earnings
Pre-earnings options volume in ICON (ICLR) plc is normal with calls leading puts 19:6. Implied volatility suggests the market is anticipating a move near 4.1%, or $4.44, after results are
Icon price target lowered to $120 from $200 at Barclays
Barclays analyst Luke Sergott lowered the firm’s price target on Icon (ICLR) to $120 from $200 and keeps an Equal Weight rating on the shares. The firm cites uncertainty around
Ademi LLP Investigates Claims of Securities Fraud against ICON plc
MILWAUKEE, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating possible securities fraud claims against ICON (NASDAQ: ICLR). The investigation results from inaccurate statements ICON may have...
Icon upgraded to Buy from Hold at Jefferies
Jefferies analyst David Windley upgraded Icon (ICLR) to Buy from Hold with a price target of $135, down from $175. The stock’s current valuation makes Icon “hard to ignore,” the
ICON plc Faces Investigation After Internal Probe Reveals Multi-Year Revenue Overstatement
(NASDAQ: ICLR) NEW YORK, Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating ICON plc (NASDAQ: ICLR) following the company's disclosure on February 12, 2026, that an internal accounti...
Icon upgraded to Buy from Hold at TD Cowen
TD Cowen analyst Charles Rhyee upgraded Icon (ICLR) to Buy from Hold with a price target of $120, down from $183. The selloff related to the company’s internal accounting investigation
Icon downgraded to Neutral from Buy at Rothschild & Co Redburn
Rothschild & Co Redburn analyst Jamie Clark downgraded Icon (ICLR) to Neutral from Buy with a price target of $100, down from $226. The firm cites the company’s announcement of
Icon price target lowered to $119 from $217 at Baird
Baird lowered the firm’s price target on Icon (ICLR) to $119 from $217 and keeps an Outperform rating on the shares. The firm is designating the shares as a bullish
Icon price target lowered to $100 from $175 at BMO Capital
BMO Capital lowered the firm’s price target on Icon (ICLR) to $100 from $175 and keeps a Market Perform rating on the shares. The company is delaying its Q4 earnings
Why this drug-research company's stock is having its worst day since 1999
Shares of Icon were plummeting on Thursday toward their worst day in decades, as the announcement of an accounting probe added to all the pressures the contract research organization sector has alread...
ICON PLC (ICLR) Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether ICON Public Limited Company (NASDAQ: ICLR) or its executive officers complied with the federal securities law...
ICON plc Provides Update on Timing of Fourth Quarter and Full Year 2025 Earnings Results and Investigation into Accounting Practices
DUBLIN--(BUSINESS WIRE)--ICON plc Provides Update on Timing of Fourth Quarter and Full Year 2025 Earnings Results and Investigation into Accounting Practices.